Rice Hall James & Associates LLC Sells 4,632 Shares of Insmed Incorporated (NASDAQ:INSM)

Rice Hall James & Associates LLC cut its holdings in Insmed Incorporated (NASDAQ:INSM) by 5.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 88,860 shares of the biopharmaceutical company’s stock after selling 4,632 shares during the period. Rice Hall James & Associates LLC’s holdings in Insmed were worth $6,135,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in INSM. Vestal Point Capital LP increased its holdings in shares of Insmed by 113.3% in the 3rd quarter. Vestal Point Capital LP now owns 1,600,000 shares of the biopharmaceutical company’s stock worth $116,800,000 after buying an additional 850,000 shares during the last quarter. TimesSquare Capital Management LLC bought a new position in Insmed during the 3rd quarter valued at about $35,322,000. Assenagon Asset Management S.A. grew its holdings in Insmed by 119.2% during the 3rd quarter. Assenagon Asset Management S.A. now owns 857,360 shares of the biopharmaceutical company’s stock valued at $62,587,000 after purchasing an additional 466,306 shares during the last quarter. Victory Capital Management Inc. grew its holdings in Insmed by 209.9% during the 3rd quarter. Victory Capital Management Inc. now owns 455,959 shares of the biopharmaceutical company’s stock valued at $33,285,000 after purchasing an additional 308,819 shares during the last quarter. Finally, Westfield Capital Management Co. LP bought a new position in Insmed during the 3rd quarter valued at about $18,377,000.

Insider Transactions at Insmed

In related news, insider Martina M.D. Flammer sold 3,344 shares of the stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $65.91, for a total transaction of $220,403.04. Following the completion of the sale, the insider now owns 102,766 shares of the company’s stock, valued at $6,773,307.06. This represents a 3.15 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Sara Bonstein sold 1,066 shares of the stock in a transaction that occurred on Friday, January 10th. The shares were sold at an average price of $63.72, for a total transaction of $67,925.52. Following the sale, the chief financial officer now directly owns 118,863 shares of the company’s stock, valued at $7,573,950.36. The trade was a 0.89 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 495,135 shares of company stock valued at $38,409,713. Company insiders own 4.60% of the company’s stock.

Insmed Price Performance

Shares of INSM opened at $79.31 on Tuesday. The company has a 50 day moving average price of $73.51 and a 200-day moving average price of $73.31. Insmed Incorporated has a fifty-two week low of $21.92 and a fifty-two week high of $82.04. The stock has a market capitalization of $14.19 billion, a PE ratio of -14.29 and a beta of 1.11. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on INSM shares. Stifel Nicolaus upped their price target on shares of Insmed from $88.00 to $97.00 and gave the company a “buy” rating in a report on Tuesday, February 11th. Truist Financial reiterated a “buy” rating and set a $105.00 price target (up from $100.00) on shares of Insmed in a report on Friday, November 1st. HC Wainwright restated a “buy” rating and issued a $90.00 target price on shares of Insmed in a research note on Friday, November 1st. Guggenheim upped their target price on shares of Insmed from $95.00 to $101.00 and gave the stock a “buy” rating in a research note on Friday, February 7th. Finally, Morgan Stanley upped their target price on shares of Insmed from $85.00 to $90.00 and gave the stock an “overweight” rating in a research note on Thursday, February 6th. One research analyst has rated the stock with a sell rating and fifteen have issued a buy rating to the stock. According to MarketBeat, Insmed currently has a consensus rating of “Moderate Buy” and an average target price of $88.71.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.